Praxis precision medicines provides corporate update and reports second quarter 2023 financial results

On track to initiate phase 3 studies for ulixacaltamide in q4 2023 after favorable end-of-phase 2 meeting with fda prax-628 phase 1 study showed consistent safety profile and target engagement in measures of qeeg activity at all doses with first administration praxis will hold an r&d portfolio day on october 2 cash of $124.3 million  as of june 30, 2023 expected to support runway into q1 2025 boston, aug. 09, 2023 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter 2023. “our four clinical-stage programs continue to make great progress, and we are excited to be advancing ulixacaltamide into phase 3,” said marcio souza, president and chief executive officer of praxis.
PRAX Ratings Summary
PRAX Quant Ranking